208 related articles for article (PubMed ID: 15261431)
21. Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
Betta PG; Magnani C; Bensi T; Trincheri NF; Orecchia S
Arch Pathol Lab Med; 2012 Mar; 136(3):253-61. PubMed ID: 22372901
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
23. [Malignant mesothelioma of the pleura. Morphometric study].
Serio G; Caniglia DM; Pennella A; Giardina C; Dalena AM; Serio R; Lettini T; Ricco R
Pathologica; 1997 Apr; 89(2):122-7. PubMed ID: 9411357
[TBL] [Abstract][Full Text] [Related]
24. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
25. Metastatic appendiceal mucinous adenocarcinoma to well-differentiated diffuse mesothelioma of the peritoneal cavity: a mimicker of florid mesothelial hyperplasia in association with neoplasms.
Tran TA; Holloway RW; Finkler NJ
Int J Gynecol Pathol; 2008 Oct; 27(4):526-30. PubMed ID: 18753969
[TBL] [Abstract][Full Text] [Related]
26. In search of a positive immunohistochemical marker for mesothelioma: an update.
Ordóñez NG
Adv Anat Pathol; 1998 Jan; 5(1):53-60. PubMed ID: 9868512
[No Abstract] [Full Text] [Related]
27. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
Lagana SM; Taub RN; Borczuk AC
Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
[TBL] [Abstract][Full Text] [Related]
28. Pathological anatomy and molecular pathology.
Krismann M; Müller KM; Jaworska M; Johnen G
Lung Cancer; 2004 Aug; 45 Suppl 1():S29-33. PubMed ID: 15261430
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
Wu M; Sun Y; Li G; Desman G; Wang B; Gil J; Burstein DE
Am J Clin Pathol; 2007 Nov; 128(5):783-7. PubMed ID: 17951200
[TBL] [Abstract][Full Text] [Related]
30. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
Brockstedt U; Gulyas M; Dobra K; Dejmek A; Hjerpe A
Am J Clin Pathol; 2000 Aug; 114(2):203-9. PubMed ID: 10941335
[TBL] [Abstract][Full Text] [Related]
31. Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure.
Tsuzuki T; Ninomiya H; Natori Y; Ishikawa Y
Pathol Int; 2008 Jul; 58(7):451-5. PubMed ID: 18577116
[TBL] [Abstract][Full Text] [Related]
32. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD
Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230
[TBL] [Abstract][Full Text] [Related]
33. Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura.
Ramael M; Van den Bossche J; Buysse C; Deblier I; Segers K; Van Marck E
Histol Histopathol; 1995 Jul; 10(3):639-43. PubMed ID: 7579812
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of pleural malignant mesothelioma in life--a practical approach.
Whitaker D; Shilkin KB
J Pathol; 1984 Jul; 143(3):147-75. PubMed ID: 6379132
[TBL] [Abstract][Full Text] [Related]
36. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.
Esposito V; Baldi A; De Luca A; Claudio PP; Signoriello G; Bolognese A; Centonze P; Giordano GG; Caputi M; Baldi F; Giordano A
Anticancer Res; 1997; 17(1B):733-6. PubMed ID: 9066611
[TBL] [Abstract][Full Text] [Related]
37. Value of morphometry, texture analysis, densitometry, and histometry in the differential diagnosis and prognosis of malignant mesothelioma.
Weyn B; Van De Wouwer G; Koprowski M; Van Daele A; Dhaene K; Scheunders P; Jacob W; Van Marck E
J Pathol; 1999 Dec; 189(4):581-9. PubMed ID: 10629562
[TBL] [Abstract][Full Text] [Related]
38. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
[TBL] [Abstract][Full Text] [Related]
39. Ultrastructural diagnosis of pleural tumors.
Stoebner P; Brambilla E
Pathol Res Pract; 1982; 173(4):402-16. PubMed ID: 6889732
[TBL] [Abstract][Full Text] [Related]
40. Podoplanin as a marker for mesothelioma.
Kimura N; Kimura I
Pathol Int; 2005 Feb; 55(2):83-6. PubMed ID: 15693854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
